References
±, cancer, tumor
CANCER, TUMOR, BLADDER TUMOR, METASTATIC DISEASE
CONSORT flowchart for the EXoRC trial. A total of 87 patients were screened, of which 60 patients were randomized. Ultimately, 25 patients of the Sevoflurane group and 26 patients of the Propofol group were included in the analysis.Western blot: Testing for EV-characteristic proteins ALIX, flotillin and CD63. Extracted EVs show positive bands for EV-characteristic proteins (Mean measured particle size and concentration. Basal, after induction of anesthesia, 30 min surgery time and at suture. Mean ± SD. Size (miRNA expression patterns of array studies in Venn diagrams. MiRNA expression of the 10 patients, regardless of the anesthetic procedure. Among others, four tumor-associated miRNAs, miR-15a-5ß, miR-17-5p, miR-21-5p and miR-451a, represent themselves as stable miRNAs and were chosen for further research (miRNA expression patterns of array studies in Venn diagrams for Sevoflurane and Propofol. Shown miRNAs were expressed within one time point by all patients of one group (Propofol or Sevoflurane). Tumor-associated miRNAs are shown in bold.Expression of selected miRNAs. Represented as fold change, relative to basal time point, for the measurement time points of anesthesia induction, 30 min of surgery and suture. Shown are miR-17-5p (miRNA expression of miR-451a. Represented as fold change, relative to basal time point, for the measurement time points of anesthesia induction, 30 min of surgery and at suture. Shown as the expression for the entire patient population (Demographics and intra- and postoperative characteristics. Demographic data from all of the patients of the study. Postoperative data refer to the next morning after surgery. M ± SD, mean and standard deviation; Md (IQR), median with interquartile range; MAC, minimal alveolar concentration; BMI, body mass index; ASA, American society of anesthesiology; UICC, Union for international cancer control; TURBT, transurethral resection of bladder tumor; T, local tumor stage, N; N, nodal tumor stage; M, presence of metastatic disease; 